• Joe Ross was named VP of strategic initiatives at Axial Biotech (Salt Lake City). Previously, Ross was VP of global marketing for Stryker Biotech. Axial Biotech makes molecular diagnostic and motion preserving technologies in the spine care market.

• Exosome Diagnostics (New York) reported two additions to its management team as the company moves forward with development of its blood-based diagnostics that can identify cancer-specific genetic mutations. Wayne Comper, PhD, was named chief scientific officer. Most recently, Comper was chief science officer of AusAm Biotechnologies. Tom Tsakeris was named director of regulatory affairs. Previously, Tsakeris was president of Devices and Diagnostics Consulting Group. Exosome Diagnostics makes genetics-based diagnostic tests with applications in oncology and endocrinology.

• Ronald Allen has been named to the board of directors of Guided Therapeutics (Norcross, Georgia). He is a former chairman/president/CEO of Delta Air Lines. Guided Therapeutics is developing a rapid and painless test for the early detection of disease that leads to cervical cancer.

• Randall H. H. Madry has been named executive director of the National Coalition for Quality Colorectal Cancer Screening and Care (Annapolis, Maryland). Madry has previously served as deputy commissioner for the North Carolina Department of Insurance. He has chaired the National Association of Insurance Commissioner's Health Plan Accountability Work Group and served as president/CEO of URAC, the American Accreditation Health Care Commission, an accreditation agency promoting quality standards and practices in healthcare.

• Philip Arlen, MD, has been named president and chief medical officer, and elected to the board of directors of Neogenix Oncology (Great Neck, New York). Previously, Arlen was director of the clinical research group, laboratory of tumor immunology and biology at the National Cancer Institute. Neogenix Oncology is a biopharmaceutical company that makes diagnostics and therapeutics for the management of serious and difficult to treat cancers.